Cancer immunotherapy with immune checkpoint inhibitors, such as those targeting CTLA-4 and PD-1/PD-L1, has now revolutionized the field of oncology by prolonging survival of patients with rapidly fatal cancers [3]. Here, CTLA4 is linked to cancer.